Erratum to Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002) (Ann Surg Oncol, (2015), 10.1245/s10434-015-4771-1);Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002)

Annals of Surgical Oncology

Volumn 22, Issue , 2015, Pages 1067-1074

  Oki, Eiji ^a   Emi, Yasunori ^b   Miyamoto, Yuji ^c   Kabashima, Akira ^d   Higashi, Hidefumi ^e   Ogata, Yutaka ^f   Ikebe, Masahiko ^g   Saeki, Hiroshi ^a   Tokunaga, Shoji ^h   Shirabe, Ken ^a   Beppu, Toru ^c   Uchida, Shinji ^f   Takatsuki, Mitsuhisa ⁱ   Sakoda, Masahiko ^j   Eguchi, Susumu ⁱ   Akagi, Yoshito ^k   Kakeji, Yoshihiro ^l   Baba, Hideo ^c   Natsugoe, Shoji ^j   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b SAISEIKAI FUKUOKA GENERAL HOSPITAL   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers   (Japan)

^e STEEL MEMORIAL YAWATA HOSPITAL   (Japan)

^f KURUME UNIVERSITY MEDICAL CENTER   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION BEPPU MEDICAL CENTER   (Japan)

^h KYUSHU UNIVERSITY HOSPITAL   (Japan)

ⁱ NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^j KAGOSHIMA UNIVERSITY   (Japan)

^k KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CETUXIMAB; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OXALIPLATIN; ANTINEOPLASTIC AGENT; DRUG COMBINATION; OTERACIL; PLATINUM COMPLEX; S 1 (COMBINATION); TEGAFUR;

ACNE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLERGIC REACTION; ALOPECIA; APPETITE DISORDER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HISTOLOGY; HUMAN; INFUSION RELATED REACTION; LIVER RESECTION; MALAISE; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PIGMENT DISORDER; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RASH; SENSORY NEUROPATHY; SIDE EFFECT; SURVIVAL RATE; TASTE DISORDER; VOMITING; WILD TYPE; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DRUG COMBINATION; FOLLOW UP; LIVER NEOPLASMS; PATHOLOGY; PROGNOSIS; SECONDARY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CETUXIMAB; COLORECTAL NEOPLASMS; DRUG COMBINATIONS; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; OXONIC ACID; PROGNOSIS; SURVIVAL RATE; TEGAFUR;

EID: 84952872895     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-015-4864-x     Document Type: Erratum

References (30)

1. Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol. 2012;17:1–29.
2. Steele G Jr, Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Biologic perspective. Ann Surg. 1989;210:127–38.
3. Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai SY, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol. 2013;31:1931–8.
4. Foster JH. Treatment of metastatic disease of the liver: a skeptic’s view. Semin Liver Dis. 1984;4:170–9.
5. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065–75.
6. Marino D, Leone F, D’Avanzo F, Ribero D, Capussotti L, Aglietta M. Potentially resectable metastatic colorectal cancer: an individualized approach to conversion therapy. Crit Rev Oncol Hematol. 2014;92:218–26.
7. Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F, et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol. 2014;25:1018–25.
8. Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, et al. Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013;11:141–52; quiz 152.
9. Benoist S, Nordlinger B. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases. Ann Surg Oncol. 2009;16:2385–90.
10. Ychou M, Rivoire M, Thezenas S, Quenet F, Delpero JR, Rebischung C, et al. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial. Ann Surg Oncol. 2013;20:4289–97.
11. Fornaro L, Lonardi S, Masi G, Loupakis F, Bergamo F, Salvatore L et al. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol. 2013;24:2062–7.
12. Wong R, Cunningham D, Barbachano Y, Saffery C, Valle J, Hickish T, et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol. 2011;22:2042–8.
13. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer. 1998;34:1715–20.
14. Nakamura M, Yamada Y, Muro K, Takahashi K, Baba H, Sasaki Y, et al. The SOFT trial: a phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer. Future Oncol. 2015;11:1471–8.
15. Yamada Y, Takahari D, Matsumoto H, Baba H, Nakamura M, Yoshida K, et al. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 2013;14:1278–86.
16. Kim ST, Hong YS, Lim HY, Lee J, Kim TW, Kim KP et al. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial. BMC Cancer. 2014;14:883.
17. Hong YS, Park YS, Lim HY, Lee J, Kim TW, Kim KP, et al. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. Lancet Oncol. 2012;13:1125–32.
18. Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757–65.
19. Van Cutsem E, Lenz HJ, Kohne CH, Heinemann V, Tejpar S, Melezinek I, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 2015;33:692–700.
20. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11:38–47.
21. Garufi C, Torsello A, Tumolo S, Ettorre GM, Zeuli M, Campanella C, et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer. 2010;103:1542–7.
22. Madi A, Fisher D, Wilson RH, Adams RA, Meade AM, Kenny SL, et al. Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial. Br J Cancer. 2012;107:1037–43.
23. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet. 2011;377:2103–14.
24. Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol. 2011;12:642–53.
25. Adams RA, Meade AM, Madi A, Fisher D, Kay E, Kenny S, et al. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. Br J Cancer. 2009;100:251–8.
26. Beppu T, Emi Y, Tokunaga S, Oki E, Shirabe K, Ueno S, et al. Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with Bevacizumab (KSCC0802 Study). Anticancer Res. 2014;34:6655–62.
27. Gruenberger T, Bridgewater J, Chau I, Alfonso P, Rivoire M, Lasserre S, et al. Randomized, phase II study of bevacizumab with mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: resectability and safety in OLIVIA. J Clin Oncol. 2013;31:3619.
28. Takahashi T, Shibata Y, Tojima Y, Tsuboi K, Sakamoto E, Kunieda K, et al. Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study. Int J Clin Oncol. 2013;18:335–42.
29. Blazer DG 3rd, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26:5344–51.
30. Kishi Y, Zorzi D, Contreras CM, Maru DM, Kopetz S, Ribero D, et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol. 2010;17:2870–6.